Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Lymphoma, Mantle-Cell Clinical Trial

— CLSGMCLPOLA  

Official title:

A Phase II, Open-label Study of Polatuzumab-vedotin (PV) in Combination With Bendamustine and Rituximab for Patients With Mantle Cell Lymphoma, Who Relapse After Previous Therapy With Bruton Tyrosine Kinase Inhibitor

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04913103
• Other study ID #: CLSG-MCL-POLA
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2021
• Est. completion date: August 31, 2027

Study information

• Verified date: May 2021
• Source: Czech Lymphoma Study Group
• Contact: Pavel Klener, prof.MD,PhD
• Phone: +420224962568
• Email: pavel.klener2[@]vfn.cz
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kinase inhibitor

Description:

Primary objective:

Efficacy: to evaluate the efficacy of the combination of polatuzumab vedotin plus bendamustine and rituximab (BR) with respect to progression-free survival (PFS)

Secondary objectives:

Efficacy: to evaluate the efficacy of polatuzumab vedotin plus BR with respect to secondary efficacy endpoints, namely overall response rate, duration of response, event free survival and overall survival; Safety objective; Exploratory objectives

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 21
• Est. completion date: August 31, 2027
• Est. primary completion date: August 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Signed written Informed Consent Form

• Adult patients with relapsed or refractory MCL after failure of BTK inhibitor-containing therapy (e.g. ibrutinib, acalabrutinib, zanubrutinib)

• Patients previously treated with bendamustine are eligible for the study treatment, in the case they had achieved objective response (CR or PR) and the last dose of bendamustine was administered = 1 year before the estimated study treatment initiation date (C1D1)

• Tumor tissue at the lymphoma relapse after failure of BTK inhibitor. In case that a re-biopsy is not possible (e.g. urgent need to start study treatment), archival tissue blocks may be used to confirm the diagnosis

• Bone marrow examination by standard trephine biopsy including flow cytometry analysis within 8 weeks before study entry

• Age 18-80 years at the time of signing Informed Consent Form

• ECOG Performance Status of 0, 1, or 2

• Life expectancy = 2 months

• Adequate hematologic function (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to the involvement of the spleen by MCL per the investigator), defined as follows:

• Hemoglobin = 80g/L

• ANC = 1,500/µL

• Platelet count = 75,000/µL Enrollment of patients with lower counts is possible only after consulting the medical monitor.

• Adequate cardiac functions according to echocardiography (ECHO) within 6 months before study entry

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 12 months after the last dose of study treatment. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.

Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.

• For women of childbearing potential, a negative serum pregnancy test result within 7 days prior to commencement of dosing. Women who are considered not to be of childbearing potential are not required to have a pregnancy test.

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 months after the last dose of polatuzumab vedotin, 3 months after the last dose of rituximab, and for at least 6 months after the last dose of bendamustine to avoid exposing the embryo for the duration of the pregnancy. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. Male patients considering preservation of fertility should bank sperm before study treatment.

Exclusion Criteria:

• Prior organ transplantation

• Current Grade = 2 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease

• History of other malignancy that could affect compliance with the protocol or interpretation of results Patients with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix at any time prior to the study are eligible Patients with any malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for = 2 years prior to enrollment are eligible Patients with low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage

1 or 2) with no requirement for therapy at any time prior to study are eligible.

• Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results.

• Recent major surgery (e.g. within 4 weeks prior to the start of Cycle 1), other than for diagnosis

• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or significant infections within 2 weeks before the start of Cycle 1.

• Clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis

• Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment

• Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):

INR > 1.5 x upper limit of normal (ULN) in the absence of therapeutic anticoagulation aPTT > 1.5 x ULN in the absence of a lupus anticoagulant

• Serum AST and ALT > 3 x ULN

• Total bilirubin > 2 x ULN Patients with documented Gilbert disease may be enrolled if total bilirubin is > 3.0 x ULN.

• Serum creatinine clearance < 40 mL/min (using Cockcroft-Gault formula or creatinine levels assessed directly from the collected urine)

• Patients with suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay)

• Positive test results for chronic hepatitis B infection defined as positive hepatitis B surface antigen (HBsAg) serology

• Patients with occult or prior hepatitis B infection defined as positive total hepatitis B core antibody and negative HBsAg may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. These patients must be willing to undergo regular DNA testing and appropriate antiviral therapy as indicated.

• Positive test results for hepatitis C virus (HCV) antibody serology testing Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

• Known history of HIV seropositive status

• Patients with a history of progressive multifocal leukoencephalopathy

• Pregnancy or lactation or intending to become pregnant during study

• CNS lymphoma In patients with clinical signs attributable to CNS lymphoma, CT scan (MRI also acceptable) of the head and examination of cerebrospinal fluid will be required prior to study treatment initiation

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Mantle-Cell

Intervention

Drug:
• Polatuzumab vedotin
treatment by a study drug polatuzumab-vedotin, i.v.
• Bendamustine Hydrochloride
treatment by a study drug bendamustin i.v.
• Rituximab
treatment by a study drug rituximab, i.v.

Locations

Country	Name	City	State
Czechia	University Hospital Brno	Brno
Czechia	University Hospital Hradec Králové	Hradec Králové
Czechia	University Hospital Olomouc	Olomouc
Czechia	University Hospital Ostrava	Ostrava
Czechia	University Hospital Plzen	Plzen
Czechia	University Hospital Kralovske Vinohrady	Prague 10
Czechia	Charles University General Hospital	Prague 2

Sponsors (1)

Lead Sponsor	Collaborator
Czech Lymphoma Study Group

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	evaluation of the efficacy of the combination of polatuzumab vedotin plus bendamustine and rituximab (BR) with respect to progression-free survival (PFS)	4 years
Secondary	overall response rate (ORR)	efficacy of polatuzumab vedotin plus BR with respect to overall response rate	4 years
Secondary	duration of response (DoR)	efficacy of PV plus BR with respect to duration of response	4 years
Secondary	event free survival (EFS)	efficacy of PV plus BR with respect to event free survival	4 years
Secondary	overall survival (OS)	efficacy of PV plus BR with respect to overall survival	4 years